Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.56
ANTH's Cash to Debt is ranked higher than
64% of the 771 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.69 vs. ANTH: 1.56 )
ANTH' s 10-Year Cash to Debt Range
Min: 0.29   Max: No Debt
Current: 1.56

F-Score: 2
Z-Score: -11.38
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -209.11
ANTH's ROE (%) is ranked lower than
57% of the 724 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. ANTH: -209.11 )
ANTH' s 10-Year ROE (%) Range
Min: -499.55   Max: -70.58
Current: -209.11

-499.55
-70.58
ROA (%) -82.48
ANTH's ROA (%) is ranked lower than
56% of the 746 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.87 vs. ANTH: -82.48 )
ANTH' s 10-Year ROA (%) Range
Min: -414.89   Max: -61.92
Current: -82.48

-414.89
-61.92
ROC (Joel Greenblatt) (%) -3478.69
ANTH's ROC (Joel Greenblatt) (%) is ranked lower than
55% of the 740 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.90 vs. ANTH: -3478.69 )
ANTH' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -210341.18   Max: -3478.69
Current: -3478.69

-210341.18
-3478.69
EBITDA Growth (%) -52.00
ANTH's EBITDA Growth (%) is ranked lower than
54% of the 592 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.60 vs. ANTH: -52.00 )
ANTH' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: -52
Current: -52

EPS Growth (%) -50.70
ANTH's EPS Growth (%) is ranked lower than
51% of the 593 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.40 vs. ANTH: -50.70 )
ANTH' s 10-Year EPS Growth (%) Range
Min: 0   Max: -50.7
Current: -50.7

» ANTH's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

ANTH Guru Trades in Q2 2013

Jim Simons 303,553 sh (New)
Louis Moore Bacon 2,000,000 sh (unchged)
» More
Q3 2013

ANTH Guru Trades in Q3 2013

Jim Simons 48,050 sh (+26.63%)
Louis Moore Bacon Sold Out
» More
Q4 2013

ANTH Guru Trades in Q4 2013

Louis Moore Bacon 224,800 sh (New)
Jim Simons 66,700 sh (+38.81%)
» More
Q1 2014

ANTH Guru Trades in Q1 2014

Jim Simons 97,400 sh (+46.03%)
Louis Moore Bacon 200,000 sh (-11.03%)
» More
» Details

Insider Trades

Latest Guru Trades with ANTH



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.70
ANTH's P/B is ranked higher than
56% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.20 vs. ANTH: 5.70 )
ANTH' s 10-Year P/B Range
Min: 0   Max: 6.7
Current: 5.7

0
6.7
EV-to-EBIT -2.00
ANTH's EV-to-EBIT is ranked higher than
52% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.97 vs. ANTH: -2.00 )
ANTH' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -2

Current Ratio 2.52
ANTH's Current Ratio is ranked higher than
72% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.31 vs. ANTH: 2.52 )
ANTH' s 10-Year Current Ratio Range
Min: 0.15   Max: 16.1
Current: 2.52

0.15
16.1
Quick Ratio 2.52
ANTH's Quick Ratio is ranked higher than
77% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.67 vs. ANTH: 2.52 )
ANTH' s 10-Year Quick Ratio Range
Min: 0.15   Max: 16.1
Current: 2.52

0.15
16.1

Valuation & Return

vs
industry
vs
history
Price/Net Cash 37.90
ANTH's Price/Net Cash is ranked higher than
84% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. ANTH: 37.90 )
ANTH' s 10-Year Price/Net Cash Range
Min: 2.01   Max: 41.88
Current: 37.9

2.01
41.88
Price/Net Current Asset Value 37.90
ANTH's Price/Net Current Asset Value is ranked higher than
79% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. ANTH: 37.90 )
ANTH' s 10-Year Price/Net Current Asset Value Range
Min: 2.01   Max: 41.88
Current: 37.9

2.01
41.88
Price/Tangible Book 5.70
ANTH's Price/Tangible Book is ranked higher than
65% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.53 vs. ANTH: 5.70 )
ANTH' s 10-Year Price/Tangible Book Range
Min: 1.96   Max: 14.46
Current: 5.7

1.96
14.46
Forward Rate of Return (Yacktman) -747.08
ANTH's Forward Rate of Return (Yacktman) is ranked lower than
55% of the 622 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.99 vs. ANTH: -747.08 )
ANTH' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -747.08

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:6TA1.Germany
Anthera Pharmaceuticals, Inc. was incorporated on September 9, 2004 in the state of Delaware. The Company is a biopharmaceutical company focused on developing and commercializing therapeutics to treat serious diseases associated with inflammation and autoimmune diseases. The Company's primary product candidate, blisibimod, targets elevated levels of B-cell activating factor, or BAFF, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus, or lupus, IgA nephropathy, lupus nephritis, vasculitis, rheumatoid arthritis, idiopathic thrombocytopenia purpura, and others. Government authorities in the United States at the federal, state and local level and other countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing, export and import of products such as those we are developing. The Company's product candidate must be approved by the FDA through the new drug application, or NDA, process, and its biological product candidate, blisibimod, must be approved by the FDA through the biologics license application, or BLA, process before they may legally be marketed in the United States. The Company's industry is highly competitive and subject to rapid and significant technological change. Its potential competitors include large pharmaceutical and biotechnology companies, specialty pharmaceutical and generic drug companies, academic institutions, government agencies and research institutions.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide